RNAi (metabolic/obesity pathway)

Class

RNA interference (siRNA) therapeutic

RNA interference (RNAi) therapeutics use short interfering RNA (siRNA) molecules to silence a chosen gene by directing the cell's own machinery to destroy its messenger RNA, the template cells use to build a protein. This particular mechanism applies siRNA to genes within the activin signaling family that influence how the body stores and releases fat and how it maintains muscle. Two genes of interest, ALK7 (also called ACVR1C) and INHBE, were identified through large human genetic studies linking naturally occurring loss-of-function variants in these genes to more favorable fat distribution and metabolic health. Silencing them lowers the corresponding protein, which in laboratory models promotes breakdown of stored fat while helping to preserve skeletal muscle, a tissue that is often lost during other weight-reduction approaches. This strategy is being explored for obesity, either alongside or as an alternative to appetite-suppressing medicines, and more broadly for metabolic conditions such as type 2 diabetes and fatty liver disease, where excess fat storage and impaired energy use are intertwined. Because chemically stabilized siRNA can produce long-lasting gene silencing, especially when linked to delivery molecules that target it to specific tissues, dosing intervals can be considerably longer than with conventional oral or injectable drugs.